Turkish Journal of Internal Medicine

Turkish Journal of Internal Medicine

Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus

Yazarlar: Şazi İMAMOĞLU

Cilt 3 , Sayı 1 , 2021 , Sayfalar 1 - 5

Konular:Genel ve Dahili Tıp

DOI:10.46310/tjim.815794

Anahtar Kelimeler:Type-2 diabetes,Oral treatment,Anti-diabetics

Özet: Type 2 diabetes is manifested by impaired insulin secretion in pancreatic beta cells, increased glucagon secretion in alpha cells, and generally has a history of insulin resistance. The treatment of glucose metabolism disorder and the resulting hyperglycemia constitute an important part of the treatment of type 2 diabetes. Glycemic targets can be targeted with A1C <7% to reduce the risk of micro and macrovascular complications in eligible patients, and A1C <6.5% to reduce the risk of diabetic chronic renal failure and retinopathy in those with low risk of hypoglycemia. We can consider the treatment of hyperglycemia in two components; lifestyle changes and glucose-lowering agent therapy.

ATIFLAR
Atıf Yapan Eserler
Henüz Atıf Yapılmamıştır
KAYNAK GÖSTER
BibTex
KOPYALA
@article{2021, title={Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus}, volume={3}, number={1–5}, publisher={Turkish Journal of Internal Medicine}, author={Şazi İMAMOĞLU}, year={2021} }
APA
KOPYALA
Şazi İMAMOĞLU. (2021). Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus (Vol. 3). Vol. 3. Turkish Journal of Internal Medicine.
MLA
KOPYALA
Şazi İMAMOĞLU. Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus. no. 1–5, Turkish Journal of Internal Medicine, 2021.
Atıf Görüntüle
PDF Görüntüle
Kaynak Görüntüle
Paylaş
Dergi Bilgileri